-
FDA Grants Breakthrough Therapy Designation to Merck, Daiichi Sankyo’s R-DXd for Platinum-Resistant Ovarian Cancer
16 Sep 2025 18:08 GMT
… Designation (BTD) to Merck and Daiichi Sankyo’s raludotatug deruxtecan (R-DXd … , global head, R&D, Daiichi Sankyo, in a press release. “The … ), disease control rate (DCR), clinical benefit rate, time to response, and …
-
US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck's raludotatug deruxtecan for patients with CDH6 expressing platinum─resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab
16 Sep 2025 04:05 GMT
… ), disease control rate (DCR), clinical benefit rate, time to response and … in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely … , is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
<![CDATA[New T-DXd Data Have the Potential to Reorder ADC Sequencing in HER2+ Breast Cancer]]>
22 Sep 2025 13:20 GMT
… -57.5%). Notably, the PFS benefit with T-DXd was consistently … trial data to confirm the benefit of T-DM1 after T … metastatic breast cancer. News release. Daiichi Sankyo. July 17, 2025. Accessed September …
-
EMA validates Daiichi Sankyo & AstraZeneca's type II variation MAA for Enhertu for previously treated patients with HER2 positive metastatic solid tumours
12 Sep 2025 06:02 GMT
… verification and description of clinical benefit in a confirmatory trial.
Enhertu … verification and description of clinical benefit in a confirmatory trial.
Enhertu … , is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
Daiichi Sankyo & AstraZeneca's Enhertu gets Japanese approval for patients with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy
26 Aug 2025 07:41 GMT
… verification and description of clinical benefit in a confirmatory trial.
Enhertu … verification and description of clinical benefit in a confirmatory trial.
Enhertu … , is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
China NMPA approves Daiichi Sankyo & AstraZeneca's Datroway for patients with previously treated metastatic HR positive, HER2 negative breast cancer
26 Aug 2025 04:13 GMT
… verification and description of clinical benefit in the confirmatory trial.
A … Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is … is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
Daiichi Sankyo and AstraZeneca’s Enhertu gains breakthrough therapy status
18 Jul 2025 12:12 GMT
… -drug conjugate (ADC), discovered by Daiichi Sankyo and collaboratively developed and marketed … further recognition of the potential benefit of Enhertu in combination with … 13 oncology-related BTD within Daiichi Sankyo’s portfolio underscore the potential …
-
US FDA grants breakthrough therapy designation to Daiichi Sankyo & AstraZeneca’s Enhertu plus pertuzumab to treat unresectable or metastatic HER2 positive breast cancer
18 Jul 2025 08:35 GMT
… verification and description of clinical benefit in a confirmatory trial.
Enhertu … verification and description of clinical benefit in a confirmatory trial.
Enhertu … , is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
26 Jun 2025 07:23 GMT
… verification and description of clinical benefit in a confirmatory trial.
… commercialised by AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating Datroway … -directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology …
-
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC
25 Jun 2025 03:46 GMT
… verification and description of clinical benefit in a confirmatory trial.
… commercialised by AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating Datroway … verification and description of clinical benefit in a confirmatory trial. …
About
© 1995-2025